← All trials
NCT06385236
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 19, 2024
- Primary completion
- Jun 30, 2027
- Completion date
- Jan 31, 2028
- First posted
- Apr 26, 2024
- Last posted
- Aug 19, 2024
- Enrollment
- 120
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of California, San DiegoLead sponsor
- Harvard UniversityCollaborator
- Harvard UniversityCollaborator
- Mayo ClinicCollaborator
- University of ArizonaCollaborator
- University of California, San DiegoOfficial
- Yale UniversityCollaborator
- University of California, San DiegoSponsor investigator
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.